Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,497 public trials 2,844 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

NCT03603795

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • CHU ANGERS - Maladies du sang Angers, France
  • CH de la Côte Basque - Hématologie Bayonne, France
  • CHU Estaing Clermont-Ferrand, France
  • CHU Grenoble - Hématologie Clinique Grenoble, France
View all 15 locations
View Trial Details
Active, not recruiting

Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)

NCT03609060

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • CHU ANGERS - Maladies du sang Angers, France
  • Ch Avignon Avignon, France
  • CH de la Côte Basque - Hématologie Bayonne, France
  • CHRU JEAN MINJOZ - Hématologie Besançon, France
View all 25 locations
View Trial Details
Active, not recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

NCT05476887

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Peking Union Medical College Hospital Beijing, China
  • Jiangsu Province Hospital Nanjing, China
  • Chinese Academy of Medical Sciences Peking Union Medical College - Institute of Hematology Blood Diseases Hospital Tianjin, China
  • Henan Cancer Hospital Zhengzhou, China
View Trial Details
Active, not recruiting

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT04475731

Conditions
Acute Lymphoblastic Leukemia, in Relapse, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica Ancona, Italy
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia Ascoli Piceno, Italy
  • Ao Di Rilievo Nazionale E Di Alta Specialità "San Giuseppe Moscati" - Avellino - Uoc Ematologia Con Unità Di Trapianto Avellino, Italy
  • Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto Bari, Italy
View all 22 locations
View Trial Details
Active, not recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

NCT03839771

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • AU-Adelaide-FLINDERS Adelaide, Australia
  • AU-Adelaide-RAH Adelaide, Australia
  • AU-Brisbane-PAH Brisbane, Australia
  • AU-Camperdown-RPA Camperdown, Australia
View all 181 locations
View Trial Details
Active, not recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • State University of New York Upstate Medical University Syracuse, New York, United States
  • UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States
View Trial Details

Related conditions